BioSpace News Archive

First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune suppression The islet autoimmune data suggest that cells with hypoimmune (HIP) edits evade allogeneic immune response and autoimmune response in a type 1 diabetes mouse model Transplanting allogeneic cells into a non-human primate without immune suppression represents a key step toward developmen

United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, and Memorial MRI & Diagnostic, a leader in diagnostic and imaging services in Texas, celebrated the installation of new technology for its patients in Katy, TX.

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced that the Company will present one-year, safety and efficacy results from its HOPE-2 open-label extension study with lead asset CAP-1002 for treating Duchenne muscular dystrophy (DMD) at this year’s Parent Project Muscular Dystrophy Conference.

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its COVID-19 vaccine (mRNA-1273) in young children ages 6 months through 5 years of age at a dose level of 25 µg.

Pfizer Inc. and BioNTech SE announced the U.S. Food and Drug Administration granted emergency use authorization of the Pfizer-BioNTech COVID-19 Vaccine as a three 3-µg dose series for children 6 months through 4 years of age.

Today, the U.S. Food and Drug Administration authorized emergency use of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 to include use in children down to 6 months of age.

Global management consulting and technology firm ZS has announced the launch of ZAIDYN Clinical Development.

Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that Co-founder and Chief Scientific Officer Dr. Michael Rudnicki has been named one of only three 2022 recipients of a prestigious grant awarded from Defeat Duchenne Canada, the country’s only national charity dedicated to ending Duchenne muscular dystrophy (“Duchenne”).

The latest market analysis report published by Reports and Data, titled ‘Global Ambulatory Surgery Center (ASC) Market – Forecast to 2028,’ thoroughly examines the Ambulatory Surgery Center (ASC) industry to provide essential data & information for the targeted readers.

The global colposcopes market is expected to reach USD 345.4 Million by 2028, according to a new report by Reports and Data.